As of November 9, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Moonlake Immunotherapeutics. The largest reported stake is Biotechnology Value Fund L P's, at 19.7%. 14 filings are on record since August 6, 2025 (Schedule 13D/A, June 29, 2026).
Who owns MoonLake Immunotherapeutics?
Sell to companies like Moonlake Immunotherapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 7,999,025 · Sole dispositive: 0 · Shared dispositive: 7,999,025 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 4,111,122 · Shared voting: 0 · Sole dispositive: 4,280,624 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Cormorant Asset Management, LP · Sole voting: 0 · Shared voting: 3,205,433 · Sole dispositive: 0 · Shared dispositive: 3,205,433 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 8,302,735 · Sole dispositive: 0 · Shared dispositive: 8,302,735 · SCHEDULE 13D/A, 2026-06-29
- · Holder: Cormorant Asset Management, LP · Percent: 6.25% · SCHEDULE 13G/A
Moonlake Immunotherapeutics has 14 Schedule 13D or 13G filings on record since 2025-08-06. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Biotechnology Value Fund L P | 19.7% | 8,302,735 | SCHEDULE 13D/A, 2026-06-29 | 2026-06-25 |
| Deep Track Capital, LP | 9.74% | 7,999,025 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 5.3% | 4,280,624 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Cormorant Asset Management, LP | 4.35% | 3,205,433 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Avoro Capital Advisors LLC | 3.15% | 2,000,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| 3.14% | 1,994,173 | SCHEDULE 13G/A, 2025-10-01 | 2025-09-30 | |
| Fmr LLC | 1.1% | 726,931 | SCHEDULE 13G/A, 2025-11-05 | 2025-09-30 |
Holding shares or following this stake? See who's behind Moonlake Immunotherapeutics and the warning signs.
Free to see. No signup.
Keep reading
More on Moonlake Immunotherapeutics and the records around it.
Moonlake Immunotherapeutics elsewhere on the record
Companies that share a holder
- Chen Bihua also filed stake reports on 1 other company: BridgeBio Oncology Therapeutics, Inc. (Jul 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Watch Moonlake Immunotherapeutics
Get an email when Moonlake Immunotherapeutics files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Moonlake Immunotherapeutics?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Moonlake Immunotherapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Moonlake Immunotherapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 0 | 8,302,735 | 0 | 8,302,735 | SCHEDULE 13D/A, 2026-06-29 |
| Bvf I Gp LLC | 0 | 8,302,735 | 0 | 8,302,735 | SCHEDULE 13D/A, 2026-06-29 |
| Biotechnology Value Fund Ii LP | 0 | 6,599,722 | 0 | 6,599,722 | SCHEDULE 13D/A, 2026-06-29 |
| Bvf Ii Gp LLC | 0 | 6,599,722 | 0 | 6,599,722 | SCHEDULE 13D/A, 2026-06-29 |
| Biotechnology Value Trading Fund OS LP | 0 | 1,039,238 | 0 | 1,039,238 | SCHEDULE 13D/A, 2026-06-29 |
| BVF Partners OS Ltd. | 0 | 1,039,238 | 0 | 1,039,238 | SCHEDULE 13D/A, 2026-06-29 |
| Bvf Gp Holdings LLC | 0 | 14,902,457 | 0 | 14,902,457 | SCHEDULE 13D/A, 2026-06-29 |
| Bvf Partners L P | 0 | 16,001,284 | 0 | 16,001,284 | SCHEDULE 13D/A, 2026-06-29 |
| Bvf Inc | 0 | 16,001,284 | 0 | 16,001,284 | SCHEDULE 13D/A, 2026-06-29 |
| Lampert Mark N | 0 | 16,001,284 | 0 | 16,001,284 | SCHEDULE 13D/A, 2026-06-29 |
| Loy Spike | 25,667 | 0 | 25,667 | 0 | SCHEDULE 13D/A, 2026-06-29 |
| Deep Track Capital, LP | 0 | 7,999,025 | 0 | 7,999,025 | SCHEDULE 13G/A, 2026-08-14 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 7,999,025 | 0 | 7,999,025 | SCHEDULE 13G/A, 2026-08-14 |
| David Kroin | 0 | 7,999,025 | 0 | 7,999,025 | SCHEDULE 13G/A, 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 4,111,122 | 0 | 4,280,624 | 0 | SCHEDULE 13G, 2026-08-14 |
| Cormorant Asset Management, LP | 0 | 3,205,433 | 0 | 3,205,433 | SCHEDULE 13G/A, 2026-08-14 |
| Bihua Chen | 0 | 3,205,433 | 0 | 3,205,433 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Moonlake Immunotherapeutics by CUSIP 61559X104 and gives its principal executive office as Dorfstrasse 29, Zug (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Fmr LLC | 9% | SCHEDULE 13G/A |
| 2025-08-14 | Avoro Capital Advisors LLC | 6.5% | SCHEDULE 13G |
| 2025-10-01 | Chen Bihua | 3.14% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 1.1% | SCHEDULE 13G/A |
| 2025-11-10 | Biotechnology Value Fund L P | 27.7% | SCHEDULE 13D/A |
| 2025-11-12 | Deep Track Capital, LP | 6.46% | SCHEDULE 13G |
| 2025-11-14 | Avoro Capital Advisors LLC | 3.15% | SCHEDULE 13G/A |
| 2026-02-17 | Cormorant Asset Management, LP | 6.1% | SCHEDULE 13G |
| 2026-04-02 | Biotechnology Value Fund L P | 22.3% | SCHEDULE 13D/A |
| 2026-05-15 | Cormorant Asset Management, LP | 6.25% | SCHEDULE 13G/A |
| 2026-06-29 | Biotechnology Value Fund L P | 19.7% | SCHEDULE 13D/A |
| 2026-08-14 | Deep Track Capital, LP | 9.74% | SCHEDULE 13G/A |
| 2026-08-14 | Cormorant Asset Management, LP | 4.35% | SCHEDULE 13G/A |
| 2026-08-14 | T. Rowe Price Investment Management, Inc. | 5.3% | SCHEDULE 13G |
Questions about who owns Moonlake Immunotherapeutics
Who owns Moonlake Immunotherapeutics?
On this page, 3 holders' latest ownership filings report 5% or more of Moonlake Immunotherapeutics: Biotechnology Value Fund L P (19.7%, Schedule 13D/A, filed 2026-06-29), Deep Track Capital, LP (9.74%, Schedule 13G/A, filed 2026-08-14) and T. Rowe Price Investment Management, Inc. (5.3%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Moonlake Immunotherapeutics?
By the share each holder's latest filing reports, the largest holders of Moonlake Immunotherapeutics on this page are Biotechnology Value Fund L P (19.7%), Deep Track Capital, LP (9.74%) and T. Rowe Price Investment Management, Inc. (5.3%).
When did Biotechnology Value Fund L P buy into Moonlake Immunotherapeutics?
The filings give report dates, not purchase dates. The earliest filing from Biotechnology Value Fund L P on this page is the Schedule 13D/A, filed 2025-11-10, reporting 27.7%; its latest, Schedule 13D/A filed 2026-06-29, reports 19.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Moonlake Immunotherapeutics
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 9, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Moonlake Immunotherapeutics. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.